Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...
The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback